Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an inhaled powder stop lung scarring? a safety trial begins

NCT ID NCT07719218

Not yet recruiting Knowledge-focused Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 1 trial tests whether an inhaled experimental drug called ICF004 is safe and how the body processes it. Healthy Chinese adults aged 18 to 50 will breathe in either a single or multiple doses of ICF004 or a placebo via a dry powder inhaler. The study aims to identify any side effects and measure drug levels in the blood. ICF004 is being developed as a potential future treatment for progressive lung scarring (interstitial lung disease).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an inhaled experimental drug called ICF004
What this could lead to
If safe, ICF004 could be tested as a treatment for progressive lung scarring (pulmonary fibrosis).
What could go wrong
This is an early phase 1 safety trial in healthy people, not patients. It cannot show whether the drug works for lung disease, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS INTERSTITIAL LUNG DISEASE (ILD)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.